BT7480, a novel fully synthetic <i>Bicycle</i> tumor-targeted immune cell agonist™ (<i>Bicycle</i> TICA™) induces tumor localized CD137 agonism

Abstract

BT7480 is a highly potent Nectin-4-dependent CD137 agonist that produces complete regressions and antitumor immunity with only intermittent drug exposure in syngeneic mouse tumor models and is well tolerated in preclinical safety species. This work supports the clinical investigation of BT7480 for the treatment of cancer in humans.